Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma
Abstract Rationale Glioblastoma multiforme (GBM) is a primary brain tumor with poor prognosis. The U.S. food and drug administration approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this treatment is frequent and fails to enhance the overall survival of...
Main Authors: | Ahmad Joshkon, Emeline Tabouret, Wael Traboulsi, Richard Bachelier, Stéphanie Simoncini, Sandrine Roffino, Carine Jiguet-Jiglaire, Bassam Badran, Benjamin Guillet, Alexandrine Foucault-Bertaud, Aurelie S. Leroyer, Françoise Dignat-George, Olivier Chinot, Hussein Fayyad-Kazan, Nathalie Bardin, Marcel Blot-Chabaud |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | Acta Neuropathologica Communications |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40478-022-01451-3 |
Similar Items
-
CD146/sCD146 in the Pathogenesis and Monitoring of Angiogenic and Inflammatory Diseases
by: Xavier Heim, et al.
Published: (2020-12-01) -
Role of CD146 (MCAM) in Physiological and Pathological Angiogenesis—Contribution of New Antibodies for Therapy
by: Ahmad Joshkon, et al.
Published: (2020-12-01) -
Soluble CD146 as a Potential Target for Preventing Triple Negative Breast Cancer MDA-MB-231 Cell Growth and Dissemination
by: Akshita Sharma, et al.
Published: (2022-01-01) -
Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis
by: Alexandrine Bertaud, et al.
Published: (2023-01-01) -
Comparison of a New <sup>68</sup>Ga-Radiolabelled PET Imaging Agent sCD146 and RGD Peptide for In Vivo Evaluation of Angiogenesis in Mouse Model of Myocardial Infarction
by: Anaïs Moyon, et al.
Published: (2021-09-01)